CLYDE MARQUIS: Open Payments
NPI 1619270998 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,487 in 72 payments from 13 companies in 2025. Trend: 2023 $512 · 2024 $940 · 2025 $2,487
Food & beverage: $2,487
| Company | Payments | Amount |
|---|---|---|
| AOP Health US, LLC | 1 | $785 |
| GlaxoSmithKline, LLC. | 27 | $569 |
| Verona Pharma, Inc. | 13 | $230 |
| AstraZeneca Pharmaceuticals LP | 6 | $165 |
| GENZYME CORPORATION | 7 | $162 |
| ABIOMED | 1 | $121 |
| Lilly USA, LLC | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 5 | $111 |
| Viatris Specialty LLC | 4 | $84 |
| Actelion Pharmaceuticals US, Inc. | 4 | $75 |
Products named: Rapiblyk, NUCALA, DUPIXENT, Ohtuvayre, TRELEGY ELLIPTA, ZEPBOUND, YUPELRI, TEZSPIRE.
Industry payments across TX — which companies pay providers there.
